ALT5 Sigma (NASDAQ:AIFC) Posts Quarterly Earnings Results

ALT5 Sigma (NASDAQ:AIFC) issued its earnings results on Monday. The company reported ($2.14) EPS for the quarter, FiscalAI reports. ALT5 Sigma had a negative net margin of 1,386.90% and a negative return on equity of 50.52%. The firm had revenue of $4.71 million during the quarter.

ALT5 Sigma Stock Performance

Shares of NASDAQ AIFC opened at $0.86 on Wednesday. The firm’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $1.49. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 0.01. ALT5 Sigma has a 12-month low of $0.73 and a 12-month high of $10.95.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in AIFC. Balyasny Asset Management L.P. acquired a new position in ALT5 Sigma during the 4th quarter worth about $26,000. Arete Wealth Advisors LLC acquired a new position in ALT5 Sigma during the 3rd quarter valued at about $28,000. Profund Advisors LLC acquired a new position in ALT5 Sigma during the 3rd quarter valued at about $28,000. Victory Capital Management Inc. acquired a new position in ALT5 Sigma during the 3rd quarter valued at about $33,000. Finally, First Citizens Bank & Trust Co. acquired a new position in ALT5 Sigma during the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 6.27% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wall Street Zen downgraded shares of ALT5 Sigma from a “sell” rating to a “strong sell” rating in a research note on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.